About a month after disclosing a $50 billion investment in its U.S. | Roche has earmarked more than $700 million to construct ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

Once again, AbbVie dominates doctors’ ranking of makers of immunology meds. | Just like last year, the Skyrizi and Rinvoq ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Medtronic has teamed up with Star Jones to get women talking about heart health. The TV personality is lending her star power ...

Get ready to rumble. In one corner, it’s President Donald Trump. In the other, it’s the pharmaceutical industry. | President ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

Even as Roche makes a major investment pledge across its U.S. business, the Swiss pharmaceutical giant isn’t neglecting its ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

Johnson & Johnson has generated evidence that the pace of oncology innovation is overwhelming physicians. | Johnson & Johnson ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...